Intrexon’s RheoSwitch Therapeutic System®
) platform has broad applicability in gene therapy. As a transcription control mechanism, RTS®
can regulate almost any payload gene creating a wide number of potential high value therapeutics. RTS®
technology enables dose-dependent, inducible gene expression through administration of a small-molecule ligand.
Clinical and preclinical datasets from RTS®
enabled therapeutics have shown precise gene regulation in vivo
and ex vivo
as well as an excellent safety profile (no dose-limiting toxicity or maximum tolerated dose identified, no off-target pharmacodynamics observed). RheoSwitch®
is currently being engineered into cell-based therapies with collaborators focused on oncology, ocular diseases, rare diseases and rare skin disorders.
Read more about the RTS®
platform in the Scientific Literature
section as well as the RheoSwitch® white paper